Update Your Colistin and Polymyxin B Protocols

April 2019

You'll see more focus on optimizing polymyxin antibiotics...due to new guidelines from the Infectious Diseases Society of America and others.

IV colistin (polymyxin E) and polymyxin B have been around for decades. But nephrotoxicity concerns limit their use.

Now we're reaching for polymyxins more often due to increases in multidrug-resistant (MDR) gram-negative organisms, such as carbapenem-resistant Enterobacteriaceae or some Pseudomonas or Acinetobacter.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote